Pharmaceutical applications of cyclodextrins: Effects on drug permeation through biological membranes

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 9, 2011, Pages 1119-1135

  Loftsson, Thorsteinn ^a   Brewster, Marcus E ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

absorption; complex; cyclodextrin; membrane; permeation

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; ALPHA CYCLODEXTRIN; ANANDAMIDE; ATENOLOL; AVOBENZONE; BETA CYCLODEXTRIN; BUPRANOLOL; CAPSAICIN; CELECOXIB; CURCUMIN; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN A; DANAZOL; DEXAMETHASONE; DEXAMETHASONE ACETATE; DICLOFENAC; DISULFIRAM; ETRETIN; GAMMA CYCLODEXTRIN; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; ITRACONAZOLE; KETOPROFEN; LIDOCAINE; MIDAZOLAM; NORPHENAZONE; UNINDEXED DRUG;

AQUEOUS SOLUTION; ARTICLE; ARTIFICIAL MEMBRANE; COMPLEX FORMATION; CREAM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG SOLUTION; DRUG STRUCTURE; DRUG UPTAKE; EYE IRRITATION; HUMAN; HYDROGEN BOND; HYDROLYSIS; LIPOPHILICITY; MEMBRANE TRANSPORT; MOLECULAR WEIGHT; NONHUMAN; POWDER; STRUCTURE ANALYSIS; SUSPENSION; TABLET; THERMODYNAMICS;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; CELL MEMBRANE; CYCLODEXTRINS; DRUG COMPOUNDING; EXCIPIENTS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PERMEABILITY; PHARMACOKINETICS; WATER;

EID: 80051674971     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01279.x     Document Type: Article

References (242)

1. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010; 62: 1607-1621.
2. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 1996; 85: 1017-1025. (Pubitemid 26338912)
3. 2O: a comparative study. Carbohydr Res 2006; 341: 270-274. (Pubitemid 43042611)
4. Antlsperger G, Schmid G,. Toxicological comparison of cyclodextrins. In:, Szejtli J, Szente L, eds. Proceedings of the Eighth International Symposium on Cyclodextrins. Budapest, Hungary, March 32-April 2, 1996. Dordrecht: Kluwer Acad. Pub, 1996: 149-155.
5. Antlsperger G,. New aspects in cyclodextrin toxicology. In:, Hedges AR, ed. Minutes of the Sixth International Symposium on Cyclodextrins. Paris: Editions de Santé, 1992: 277-283.
6. Pitha J, et al,. Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. Int J Pharm 1986; 29: 73-82. (Pubitemid 16162498)
7. Buedenbender S, Schulz GE,. Structural base for enzymatic cyclodextrin hydrolysis. J Mol Biol 2009; 385: 606-617.
8. Szejtli J,. The metabolism, toxicity and biological effects of cyclodextrins. In:, Duchêne D, ed. Cyclodextrins and Their Uses. Paris: Editions de Santé, 1987: 173-212.
9. Munro IC, et al,. Safety assessment of γ-cyclodextrin. Regul Toxicol Pharmacol 2004; 39 (Suppl. 1): S3-S13.
10. Irie T, Uekama K,. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86: 147-162. (Pubitemid 27078377)
11. Stella VJ, He Q,. Cyclodextrins. Tox Pathol 2008; 36: 30-42.
12. De Bie ATHJ, et al,. Disposition of 14C-γ-cyclodextrin in germfree and conventional rats. Regul Toxicol Pharmacol 1998; 27: 150-158. (Pubitemid 28377346)
13. Van Ommen B, et al,. Disposition of 14C-α-cyclodextrin in germ-free and conventional rats. Regul Toxicol Pharmacol 2004; 39: S57-S66. (Pubitemid 38953103)
14. Zhou H, et al,. A pharmacokinetic study of intravenous intraconazole followed by oral administration of intraconazole capsules in patients with advanced human immunodeficiency virus infection. J Clin Pharmacol 1998; 38: 593-602. (Pubitemid 28354896)
15. Stella VJ, et al,. Mechanism of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 1999; 36: 3-16. (Pubitemid 29074473)
16. Adam JM, et al,. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45: 1806-1816. (Pubitemid 34415376)
17. Welliver M,. New drug sugammadex: a selective relaxant binding agent. AANA J 2006; 74: 357-363. (Pubitemid 44546895)
18. Perry CS, et al,. The binding interaction of synthetic ozonide antimalarials with natural and modified β-cyclodextrins. J Pharm Sci 2006; 95: 146-158.
19. Lipinski CA,. Drug-like properties and the cause of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249. (Pubitemid 32239479)
20. Lipinski CA, et al,. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26. (Pubitemid 33653411)
21. Loftsson T, et al,. Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation. Int J Pharm 1995; 115: 255-258.
22. Chen C-Y, et al,. Effect of hydroxypropyl-β-cyclodextrin on the solubility, photostability and in-virto permeability of alkannin/shikonin enantiomers. Int J Pharm 1996; 141: 171-178. (Pubitemid 26302923)
23. Yang J, et al,. Influence of hydroxypropyl-β-cyclodextrin on transdermal penetration and photostability of avobenzone. Eur J Pharm Biopharm 2008; 69: 605-612.
24. Uekama K, et al,. Improvement in the percutaneous absorption of beclomethasone dipropionate by γ-cyclodextrin complexation. J Pharm Pharmacol 1985; 37: 532-535. (Pubitemid 15043034)
25. Arima H, et al,. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by β-cyclodextrin derivatives in hydrophilic ointment. Chem Pharm Bull 1996; 44: 582-586.
26. Arima H, et al,. Enhancement of antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by β-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats. Pharm Res 1990; 7: 1152-1156.
27. Babu RJ, Pandit JK,. Effect of cyclodextrins on the complexation and transdermal delivery of bupranolol through rat skin. Int J Pharm 2004; 271: 155-165. (Pubitemid 38210093)
28. Zi P, et al,. Effect of HPβCD on solubility and transdermal delivery of capsaicin through rat skin. Int J Pharm 2008; 358: 151-158.
29. Ventura CA, et al,. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. Int J Pharm 2006; 314: 37-45.
30. Hegge AB, et al,. In vitro release of curcumin from vehicles containing alginate and cyclodextrin. Studies of curcumin and curcuminoides. XXXIII. Pharmazie 2008; 63: 585-592.
31. Lopez RFL, et al,. Influence of cyclodextrin complexation on the in vitro permeation and skin metabolism of dexamethasone. Int J Pharm 2000; 200: 127-132.
32. Loftsson T, et al,. The effects of cyclodextrins on transdermal delivery of drugs. Eur J Pharm Biopharm 1991; 37: 30-33.
33. Kear CL, et al,. Investigation into the mechanism by which cyclodextrins influence transdermal drug delivery. Drug Dev Ind Pharm 2008; 34: 692-697. (Pubitemid 351962339)
34. Preiss A, et al,. Penetration of hydrocortisone into excised human skin under the influence of cyclodextrins. Pharmazie 1995; 50: 121-126.
35. Chang SL, Banga AK,. Transdermal iontophoretic delivery of hydrocortisone from cyclodextrin solutions. J Pharm Pharmacol 1998; 50: 635-640. (Pubitemid 28297227)
36. Loftsson T, et al,. The influence of 2-hydroxypropyl-β-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone. Drug Dev Ind Pharm 1994; 20: 1699-1708. (Pubitemid 24173010)
37. Loftsson T, Sigurðardottir AM,. The effect of polyvinylpyrrolidone and hydroxypropyl methylcellulose on HPβCD complexation of hydrocortisone and its permeability through hairless mouse skin. Eur J Pharm Sci 1994; 2: 297-301. (Pubitemid 24360863)
38. Sigurdardottir AM, Loftsson T,. The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin. Int J Pharm 1995; 126: 73-78. (Pubitemid 26018573)
39. Masson M, et al,. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Controlled Release 1999; 59: 107-118. (Pubitemid 29187198)
40. Iervolino M, et al,. Membrane penetration enhancement of ibuprofen using supersaturation. Int J Pharm 2000; 198: 229-238. (Pubitemid 30184859)
41. Okamoto H, et al,. Effects of β-cyclodextrin and di-O-methyl-β-cyclodextrin on the percutaneous absorption of butylparaben, indomethacin and sulfanilic acid. Int J Pharm 1986; 30: 35-45. (Pubitemid 16101994)
42. Kawahara K, et al,. Effect of diethyl β-cyclodextrin on the release and absorption behaviour of indomethacin from ointment bases. STP Pharma Sci 1992; 2: 506-513. (Pubitemid 23012602)
43. Batzdorf T, Mullergoymann CC,. Release of ketoprofen from aqueous systems in the presence of hydrophilic β-cyclodextrin derivatives. Pharmazutische Ind 1993; 55: 857-860. (Pubitemid 23311115)
44. Vollmer V, et al,. In vivo skin pharmacokinetics of liarozole: percutaneous absorption studies with different formulations of cyclodextrin derivatives in rats. Int J Pharm 1993; 99: 51-58.
45. Dollo G, et al,. Complexation between local anaesthetics and β-cyclodextrin derivatives-ralationship between stability constants and in vitro membrane permeability of bupivacaine and lidocaine from their complexes. STP Pharma Sci 1998; 8: 189-195. (Pubitemid 28562416)
46. Loftsson T, Bodor N,. The pharmacokinetics and transdermal delivery of loteprednol etabonate and related soft steroids. Adv Drug Deliv Rev 1994; 14: 293-299. (Pubitemid 24189166)
47. Lee BJ, et al,. Percutaneous absorption and model membrane variations of melantonin in aqueous-based propylene glycol and 2-hydroxypropyl-β- cyclodextrin vehicles. Arch Pharm Res 1998; 21: 503-507.
48. Bounoure F, et al,. Effect of partially methylated β cyclodextrin on percutaneous absorption of metopimazine. J Incl Phenom Macroc Chem 2007; 57: 191-195.
49. Tanaka M, et al,. Effect of 2-hydroxypropyl-β-cyclodextrin on percutaneous absorption of methyl paraben. J Pharm Pharmacol 1995; 47: 897-900. (Pubitemid 26020147)
50. Tenjarla S, et al,. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J Pharm Sci 1998; 87: 425-429. (Pubitemid 28175801)
51. Celebi N, et al,. The effect of β-cyclodextrin and penetration additives on the release of naproxen from ointment bases. Pharmazie 1993; 48: 914-917. (Pubitemid 24023046)
52. Legendre JY, et al,. Effects of β-cyclodextrins on skin: implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977. Eur J Pharm Sci 1995; 3: 311-322.
53. Doliwa A, et al,. In vitro iontophoretic delivery of piroxicam from hydroxypropyl-β-cyclodextrin-pyroxicam complexes. In: Proceedings of the 27th International Symposium on Controlled Release Bioactive Materials Paris: CRS, 2000: 7408.
54. Doliwa A, et al,. Influence of piroxicam: hydroxypropyl-beta-cyclodextrin complexation on the in vitro permeation and skin retention of piroxicam. Skin Pharmacol Appl Skin Physiol 2001; 14: 97-107. (Pubitemid 32375196)
55. Uekama K, et al,. Improvement of percutaneous absorption of prednisolone by β- and γ-cyclodextrin complexations. Chem Pharm Bull 1987; 35: 2910-2913. (Pubitemid 17135849)
56. Adachi H, et al,. Inhibitory effect of prostaglandin E1 on laurate-induced peripheral vascular occlusive sequelae in rabbits; optimized topical formulation with β-cyclodextrin derivative and penetration enhancer HPE-101. J Pharm Pharmacol 1992; 44: 1033-1035.
57. 1 through hairless mouse skin: combined use of carboxymethyl-ethyl- β-cyclodextrin and penetration enhancers. J Pharm Pharmacol 1992; 44: 119-121.
58. Adachi H, et al,. Combination effects of O-carboxymethyl-O-ethyl-β- cyclodextrin and penetration enhancer HPE-101 on transdermal delivery of prostaglandin-E(1) in hairless mice. Eur J Pharm Sci 1993; 1: 117-123. (Pubitemid 24055796)
59. Yuzuriha S, et al,. Topical application of prostaglandine E1 ointment to cutaneous wounds in ischemic rabbit ears. Eur J Plast Surg 1999; 22: 225-229. (Pubitemid 29403355)
60. Szeman J, et al,. Enhanced percutaneous absorption of homogenized tolnaftate/β-cyclodextrin polymer ground mixture. Drug Des Deliv 1987; 1: 325-332. (Pubitemid 18065566)
61. Amdidouche D, et al,. Evaluation by laser-doppler velocimetry of the attenuation of tretioin induced skin irritation by β-cyclodextrin complexation. Int J Pharm 1994; 111: 111-116.
62. Montassier P, et al,. In vitro release study of tretinoin from tretinoin/cyclodextrin derivative complexes. J Inclusion Phenom Mol Recog Chem 1998; 31: 213-218.
63. Gerlóczy A, et al,. Percutaneous absorption of heptakis-(2,6-di-O-14C-methyl)-β-cyclodextrin in rats. In:, Huber O, Szejtli J, eds. Proceedings of the Fourth International Symposium on Cyclodextrins. Dordrecht: Kluwer Academic Publishers, 1988: 415-420.
64. Loftsson T, Masson M,. Cyclodextrins in topical drug formulations: theory and practice. Int J Pharm 2001; 225: 15-30. (Pubitemid 32728196)
65. Vitória M, et al,. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J Pharm Pharmacol 1997; 49: 397-402.
66. Arima H, et al,. Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration activation of ethyl 4-biphenylyl acetate in hairless mouse skin. Eur J Pharm Sci 1998; 6: 53-59. (Pubitemid 28035225)
67. Preiss A, et al,. In-vitro hydrocortisone release from ointments in presence of cyclodextrins. Pharmazie 1994; 49: 902-906. (Pubitemid 24381211)
68. Loftsson T, et al,. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci 2007; 96: 2532-2546. (Pubitemid 47597809)
69. Felton LA, et al,. Influence of hydroxypropyl-β-cyclodextrin on transdermal permeation and skin accumulation of oxybenzone. Drug Dev Ind Pharm 2002; 28: 1117-1124. (Pubitemid 35278835)
70. Sarveiya V, et al,. Inclusion complexation of the sunscreen 2-hydroxy-4-methoxy benzophenone (oxybenzone) with hydroxypropyl-β- cyclodextrin: effect on membrane diffusion. J Incl Phenom Macroc Chem 2004; 49: 275-281. (Pubitemid 40684506)
71. Felton LA, et al,. Influence of cyclodextrin complexation on the in vivo photoprotective effects of oxybenzone. Drug Dev Ind Pharm 2004; 30: 95-102. (Pubitemid 38240480)
72. Loftsson T, et al,. Topically effective ocular hypertensive acetazolamide and ethoxyzolamide formulations in rabbits. J Pharm Pharmacol 1994; 46: 503-504. (Pubitemid 24179546)
73. Loftsson T, et al,. Topically effective acetazolamide eye-drop solution in man. Pharm Sci 1996; 2: 277-279. (Pubitemid 28121824)
74. Granero GE, Longhi MR,. Promishing complexes of acetazolamide for topical ocular administration. Expert Opin Drug Deliv 2010; 7: 943-953.
75. Jarho P, et al,. Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. Int J Pharm 1996; 137: 209-217.
76. Pate DW, et al,. Effects of topical anandamides on intraocular pressure in normotensive rabbits. Life Sci 1996; 58: 1849-1860. (Pubitemid 26164609)
77. Pate DW, et al,. Effect of the CB 1 receptor antagonist, SR 141716A, on cannabinoid-induced ocular hypertension in normotensive rabbits. Life Sci 1998; 63: 2181-2188. (Pubitemid 28545178)
78. Cheeks L, et al,. Influence of vehicle and anterior chamber protein concentration on cyclosporin penetration through the isolated rabbit cornea. Curr Eye Res 1992; 11: 641-649.
79. Kanai A, et al,. The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. Transplant Proc, book1 1989; 21: 3150-3152. (Pubitemid 19124695)
80. Sasamoto Y, et al,. Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis. Ophthalmologica 1991; 203: 118-125.
81. Kearse EC, et al,. Influence of dehydroepiandrosterone on rabbit intraocular pressure. Ophthalmic Res 2001; 33: 42-47.
82. Usayapant A, et al,. Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm Res 1991; 12: 1495-1499.
83. Loftsson T, et al,. The effect of hydroxypropyl methylcellulose on release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations. Int J Pharm 1994; 104: 181-184. (Pubitemid 24073703)
84. Kristinsson JK, et al,. Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Invest Ophthalmol Vis Sci 1996; 37: 1199-1203.
85. Gavrilin MV, et al,. Dexamethasone eye drops based on the products of its interaction with 2-hydroxypropyl-β-cyclodextrin: synthesis and study. Pharm Chem J 1999; 33: 160-163.
86. Loftsson T, et al,. Dexamethasone delivery to posterior segment of the eye. J Incl Phenom Macroc Chem 2007; 57: 585-589.
87. Loftsson T, et al,. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 2007; 59: 629-635. (Pubitemid 47051105)
88. Sigurdsson HH, et al,. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 2007; 85: 598-602. (Pubitemid 47316756)
89. Reer O, et al,. In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to commercial product voltaren ophtha. J Pharm Sci 1994; 83: 1345-1349. (Pubitemid 24282344)
90. Jarho P, et al,. The use of cyclodextrins in ophthalmic formulations of dipivefrin. Int J Pharm 1997; 153: 225-233. (Pubitemid 27308666)
91. Nagai N, et al,. Delay in ICR/f rat lens opacification by the instillation of eye drops containing disulfiram and hydroxypropyl-β- cyclodextrin inclusion complex. Biol Pharm Bull 2007; 30: 1529-1534. (Pubitemid 47282211)
92. Ito Y, et al,. Reduction of intraocular pressure by the installation of eye drops containing disulfiram induced with 2-hydroxypropyl-β-cyclodextrin in rabbits. Biol Pharm Bull 2010; 33: 1574-1578.
93. Jansook P, et al,. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 2010; 76: 208-214.
94. Loftsson T, et al,. Enalaprilat and enalapril maleate eye drops lower intraocular pressure in rabbits. Acta Ophthalmol Scand 2010; 88: 337-341.
95. Morita Y, et al,. Effect of hydroxypropyl-γ-cyclodextrin on ocular penetration of fluorometholone in vitro. In: 23rd International Symposium on Controlled Release Bioactive Materials. Kyoto, Japan: Controlled Release Society, 1996: 451-452. (Pubitemid 26294143)
96. Bary AR, et al,. Considerations in the use of hydroxypropyl-β- cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur J Pharm Biopharm 2000; 50: 237-244.
97. Davies NM, et al,. Evaluation of a hydrocortisone/hydroxypropyl-β- cyclodextrin solution for ocular drug delivery. Int J Pharm 1997; 156: 201-209. (Pubitemid 27400009)
98. Zhang J, et al,. Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits. J Ocul Pharmacol Ther 2008; 24: 501-506.
99. Reddy IK, et al,. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 1996; 12: 159-167. (Pubitemid 26164793)
100. Siefert B, Keipert S,. Influence of α-cyclodextrin and hydroxyalkylated β-cyclodextrin derivatives on the in vitro corneal uptake and permeation of aqueous pilocarpine-HCl solutions. J Pharm Sci 1997; 86: 716-720. (Pubitemid 27248822)
101. Freedman KA, et al,. Beta-cyclodextrins enhance bioavailability of pilocarpine. Curr Eye Res 1993; 12: 641-647. (Pubitemid 23238692)
102. Keipert S, et al,. Interactions between cyclodextrins and pilocarpine-as an example of a hydrophilic drug. Int J Pharm 1996; 142: 153-162. (Pubitemid 26354640)
103. Järvinen K, et al,. The effect of modified β-cyclodextrin, SBE4-β-CD, on the aqueous solubility and ocular absorption of pilocarpine. Curr Eye Res 1994; 13: 891-905.
104. Wheeler LA,. The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension. 3221991: Eur. Pat. #O 435 682 A3.
105. Cappello B, et al,. Formulation and preliminary in vivo testing of rufloxacin-cyclodextrin ophthalmic solutions. J Incl Phenom Macroc Chem 2002; 44: 173-176. (Pubitemid 38075686)
106. Siefert B, et al,. Influence of cyclodextrins on the in vitro permeability and in vivo ocular distribution of thalidomide. J Ocul Pharmacol Ther 1999; 15: 429-438. (Pubitemid 29480960)
107. Green K, Kearse EC,. Ocular penetration of topical ?9- tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000; 21: 566-570.
108. 9- tetrahydrocannabinol. Curr Eye Res 2000; 20: 496-501.
109. Loftsson T, Järvinen T,. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999; 36: 59-79. (Pubitemid 29074477)
110. Loftsson T, et al,. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 2008; 63: 171-179. (Pubitemid 351449926)
111. Loftsson T, Stefánsson E,. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm 1997; 23: 473-481. (Pubitemid 27241126)
112. Järvinen T, et al,. Sulfobutyl ether β-cyclodextrin (SBE-β-CyD) in eye drops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J Ocul Pharmacol Ther 1995; 11: 95-106.
113. Jarho P, et al,. Modified β-cyclodextrin (SBE7-β-CyD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J Pharm Pharmacol 1996; 48: 264-270.
114. Suhonen P, et al,. Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharmaceutical Res 1995; 12: 529-533.
115. Chavanpatil MD, Vavia PR,. The influence of absorption enhancers on nasal absorption of acyclovir. Eur J Pharm Biopharm 2004; 57: 483-487. (Pubitemid 38490566)
116. Hermens WAJJ, et al,. Nasal absorption enhancement of 17β-estradiol by dimethyl-β-cyclodextrin in rabbits and rats. Pharm Res 1990; 7: 500-503. (Pubitemid 20322201)
117. Irie T, et al,. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm 1992; 84: 129-139.
118. Loftsson T, et al,. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001; 212: 29-40. (Pubitemid 32121948)
119. Dale O, et al,. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharm Pharmacol 2006; 58: 1311-1318. (Pubitemid 44580561)
120. Gu F-G, et al,. Preparation of prostaglandin E1-hydroxypropyl-β- cyclodextrin complex and its nasal delivery in rats. Int J Pharm 2005; 290: 101-108. (Pubitemid 40139049)
121. Brown GA, et al,. Acute hormonal response to sublingual androstenediol in young men. J Appl Physiol 2002; 92: 142-146. (Pubitemid 34669999)
122. Figueiras A, et al,. In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm 2009; 71: 339-345.
123. Jug M, et al,. Novel cyclodextrin-based film formulation intended for buccal delivery of atenolol. Drug Dev Ind Pharm 2009; 35: 796-807.
124. Mannila J, et al,. Precipitation complexation method produces cannabidiol/β-cyclodextrin inclusion complex suitable for sublingual administration of cannabidiol. J Pharm Sci 2007; 96: 312-319. (Pubitemid 46363562)
125. Mannila J, et al,. Cyclodextrins and chitosan derivatives in sublingual delivery of low solubility peptides: a study using cyclosporin A, alpha-cyclodextrin and quaternary chitosan N-betainate. Int J Pharm 2010; 381: 19-24.
126. Yoo SD, et al,. Increased bioavailability of clomipramine after sublingual administration in rats. J Pharm Sci 1999; 88: 1119-1121. (Pubitemid 29526295)
127. Badawy SIF, et al,. Bioavailability of danazol-hydroxypropyl-β- cyclodextrin complex by different routes of administration. Int J Pharm 1996; 145: 137-143.
128. Jain AC, et al,. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 β-cyclodextrin (SBE 7) complexes. J Pharm Sci 2002; 91: 1659-1668. (Pubitemid 34680228)
129. Hoon TJ, et al,. Bioequivalence of 17β-estradiol hydroxypropyl-β-cyclodextrin complex in postmenopausal women. J Clin Pharmacol 1993; 33: 1116-1121. (Pubitemid 24002903)
130. Fridriksdóttir H, et al,. Design and in vivo testing of 17β-estradiol-HPβCD sublingual tablets. Pharmazie 1996; 51: 39-42. (Pubitemid 26056298)
131. Loftsson T, et al,. Sublingual delivery of 17β-estradiol from cyclodextrin containing tablets. Pharmazie 2003; 58: 358-359. (Pubitemid 36604920)
132. Mura P, et al,. Development of mucoadhesive films for buccal administration of flufenamic acid: effect of cyclodextrin complexation. J Pharm Sci 2010; 99: 3019-3029.
133. 9-tetrahydrocannabinol in rabbits. Life Sci 2006; 78: 1911-1914.
134. Cabral-Marques H, Almeida R,. Optimization of spray-drying process variables for dry powder inhalation (DPI) formulations of corticosteroid/ cyclodextrin inclusion complexes. Eur J Pharm Biopharm 2009; 73: 121-129.
135. Kinnarinen T, et al,. Pulmonary deposition of a budesonide/γ- cyclodextrin complex in vitro. J Controlled Release 2003; 90: 197-205. (Pubitemid 36694963)
136. Matilainen L, et al,. In vitro evaluation of cyclodextrin complexation on pulmonary deposition of a peptide, cyclosporin A. Int J Pharm 2006; 318: 41-48. (Pubitemid 43963296)
137. Yang W, et al,. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution. Eur J Pharm Sci 2010; 39: 336-347.
138. Sato T, et al,. A novel administration route of edaravone-II: mucosal absorption of edaravone from edaravone/hydroxypropyl-β-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite. Pharmacology 2010; 85: 88-94.
139. Kim JK, et al,. Thermo-reversible flurbiprofen liquid suppository with HP-β-CD as a solubility enhancer: improvement of rectal bioavailability. J Incl Phenom Macroc Chem 2009; 64: 265-272.
140. Francois M, et al,. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. AAPS PharmSci 2003; 5: 1.
141. Cevher E, et al,. Preparation and characterisation of natamycin: γ-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations. J Pharm Sci 2008; 97: 4319-4335.
142. Marttin E, et al,. Efficiency, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target 1998; 6: 17-36. (Pubitemid 28499586)
143. Merkus FWHM, et al,. Cyclodextrin in nasal drug delivery. Adv Drug Deliv Rev 1999; 36: 41-57.
144. Kublik H, et al,. Nasal absorption of 17β-estradiol from different cyclodextrin inclusion formulations in sheep. Eur J Pharm Biopharm 1996; 42: 320-324. (Pubitemid 26384366)
145. Richter T, Keipert S,. In vitro permeation studies comparing bovine nasal mucosa, porcine cornea and artificial membrane: androstenedione in microemulsions and their components. Eur J Pharm Biopharm 2004; 58: 137-143. (Pubitemid 38781014)
146. Cabral Marques HM, et al,. Studies of cyclodextrin inclusion complexes. III. The pulmonary absorption of β-, DM-β- and HP-β-cyclodextrins in rabbits. Int J Pharm 1991; 77: 297-302.
147. Hussain A, et al,. Absorption enhancers in pulmonary protein delivery. J Controlled Release 2004; 94: 15-24. (Pubitemid 37542374)
148. Evrard B, et al,. Cyclodextrins as a potential carrier in drug nebulization. J Controlled Release 2004; 96: 403-410. (Pubitemid 38553919)
149. Luengo J, et al,. Preliminary pharmacokinetic study of different preparations of acyclovir with β-cyclodextrin. J Pharm Sci 2002; 91: 2593-2598. (Pubitemid 35379416)
150. Evrard B, et al,. Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-β-cyclodextrin. J Controlled Release 2002; 85: 45-50. (Pubitemid 35449452)
151. García JJ, et al,. Bioavailability and efficiacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm 2003; 250: 351-358. (Pubitemid 36084359)
152. Castillo JA, et al,. Preparation and characterization of albendazole β-cyclodextrin complexes. Drug Dev Ind Pharm 1999; 25: 1241-1248.
153. Kalaiselvan R, et al,. Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Pharmazie 2007; 62: 604-607. (Pubitemid 47326167)
154. Ren K, et al,. Physicochemical characteristics and oral bioavailability of andrographolide complexed with hydroxypropyl-β-cyclodextrin. Pharmazie 2009; 64: 515-520.
155. Wong JW, Yuen KH,. Improved oral bioavailability of artemisinin through inclusion complexation with β- and γ-cyclodextrins. Int J Pharm 2001; 227: 177-185. (Pubitemid 32868771)
156. El-Gindy GA, et al,. Preparation, pharmacokinetic and pharmacodynamic evaluation of carbamazepine inclusion complexes with cyclodextrins. STP Pharma Sci 2002; 12: 369-378. (Pubitemid 35407912)
157. Brewster ME, et al,. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J Pharm Sci 1997; 86: 335-339. (Pubitemid 27113768)
158. Betlach CJ, et al,. Oral pharmacokinetics of carbamazepine in dogs from commercial tablets and a cyclodextrin complex. J Pharm Sci 1993; 82: 1058-1060. (Pubitemid 23314113)
159. Choudhury S, Nelson KF,. Improvement of oral bioavailability of carbamazepine by inclusion in 2-hydroxypropyl-β-cyclodextrin. Int J Pharm 1992; 85: 175-180.
160. Koester LS, et al,. Bioavailability of carbamazepine:β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur J Pharm Sci 2004; 22: 201-207. (Pubitemid 38668685)
161. Hirayama F, et al,. Crystallization and polymorphic transition behavior of chloramphemicol palmitate in 2-hydroxypropyl-β-cyclodextrin matrix. Eur J Pharm Biopharm 1997; 5: 23-30. (Pubitemid 27046432)
162. Patel SG, Rajput SJ,. Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes. AAPS PharmSciTech 2009; 10: 660-669.
163. Tokumura T, et al,. Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 1985; 74: 496-497. (Pubitemid 15112950)
164. Tokumura T, et al,. Enhancement of bioavailability of cinnarizine from its β-cyclodextrin complex on oral administration with DL-phenylalanine as a competing agent. J Pharm Sci 1986; 75: 391-394. (Pubitemid 16137110)
165. Järvinen T, et al,. β-Cyclodextrin derivatives, SBE4-β-CD and HP-β-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J Pharm Sci 1995; 84: 295-299.
166. Miyake K, et al,. Enhanced absorption of cyclosporin A by complexation with dimethyl-β-cyclodextrin in bile duct-cannulated and -noncannulated rats. Biol Pharm Bull 1999; 22: 66-72. (Pubitemid 29081060)
167. Miyake K, et al,. Improved solubility and oral bioavailability of cyclosporin A by hydrophilic cyclodextrin complexation. In:, Torres Labandeira JJ, Vila-Jato JL, eds. Proceedings of the Ninth International Symposium on Cyclodextrins. Dordrecht: Kluwer Academic Publishers, 1999: 293-296.
168. Badawy SIF, et al,. Characterization and bioavailability of danazol-hydroxypropyl-β-cyclodextrin coprecipitates. Int J Pharm 1996; 128: 45-54.
169. Liversidge GG, Cundy KC,. Particle-size reduction for improvement of oral bioavailability of hydrophobic drugs. 1. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995; 125: 91-97.
170. Corvi Mora P, et al,. Enhancement of dehydroepianhydrosterone solubility and bioavailability by ternary complexation with a-cyclodextrin and glycine. J Pharm Sci 2003; 92: 2177-2184.
171. Uekama K, et al,. Improvement of the oral bioavailability of digitalis glycosides by cyclodextrin complexation. J Pharm Sci 1983; 72: 1338-1341. (Pubitemid 14229750)
172. Le Corre P, et al,. Influence of hydroxypropyl-β-cyclodextrin and dimethyl-β-cyclodextrin on diphenhydramine intestinal absorption in a rat in situ model. Int J Pharm 1998; 169: 221-228. (Pubitemid 28345258)
173. Ricevuti G, et al,. Pharmacokinetics of dipyridamole-β-cyclodextrin complex in healthy volunteers after single and multiple doses. Eur J Drug Metab Pharmacokinet 1991; 16: 197-201.
174. Stracciari GL, et al,. Pharmacokinetics of dipyridamole-β- cyclodextrin complex in dogs. Arch Int Pharmacodyn Ther 1989; 300: 7-13.
175. Miyaji T, et al,. Improvement of oral bioavailability of fenbufen by cyclodextrin complexation. Acta Pharm Nord 1992; 4: 17-22.
176. Géczy J, et al,. The inclusion of fluoxitine into γ-cyclodextrin increases its bioavailability: bahavioural, electrophysiological and pharmacokinetic studies. Psychopharmacologia 2000; 151: 328-334.
177. Tokumura T, et al,. Improvement of oral bioavailability of flurbiprofen from flurbiprofen/β-cyclodextrin inclusion complex by action of cinnarizine. Eur J Pharm Biopharm 2009; 73: 202-204.
178. Savolainen J, et al,. Coadministration of a water-soluble polymer increases the usefulness of cyclodextrins in solid dosage forms. Pharm Res 1998; 15: 1696-1701. (Pubitemid 28524579)
179. Jayachandra Babu R, Pandit JK,. Enhancement of dissolution rate and hypoglycemic activity of glibenclamide with β-cyclodextrin. STP Pharma Sci 1995; 5: 196-201.
180. Aggarwal S, et al,. Studies on solubility and hypoglycemic activity of gliclazide β-cyclodextrin-hydroxypropylmethylcellulose complexes. Pharmazie 2002; 57: 191-193. (Pubitemid 34213912)
181. Sridevi S, et al,. Enhancement of dissolution and oral bioavailability of gliquidone with hydroxy propyl-β-cyclodextrin. Pharmazie 2003; 58: 807-810. (Pubitemid 37462464)
182. Uekama K, et al,. Improvement of dissolution and absorption characteristics of indomethacin by water-soluble a-cyclodextrin-epichlorohydrin polymer. Acta Pharm Suec 1987; 24: 27-36.
183. Jambhekar S, et al,. The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl-β- cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes. Int J Pharm 2004; 270: 149-166. (Pubitemid 38077096)
184. Ahn HJ, et al,. Effects of cyclodextrin derivatives on bioavailability of ketoprofen. Drug Dev Ind Pharm 1997; 23: 397-401. (Pubitemid 27186409)
185. Emara LH, et al,. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev Ind Pharm 2002; 28: 795-807. (Pubitemid 34977797)
186. Uekama K, et al,. Inhibitory effect of 2-hydroxypropyl-β- cyclodextrin on crystal-growth of nifedipine during storage-superior dissolution and oral bioavailability compared with polyvinylpyrrolidone K-30. J Pharm Pharmacol 1992; 44: 73-78.
187. Wang Z, et al,. In-vivo and in-vitro evaluations of modified-release oral dosage form of nifedipine by hybridization of hydoxypropyl-β-cyclodextrin and hydroxypropylcellulose in dogs. J Pharm Pharmacol 1994; 46: 505-507. (Pubitemid 24179547)
188. Chowdary KPR, Kamalakara RG,. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with β-cyclodextrin. Pharmazie 2003; 58: 721-724. (Pubitemid 37328402)
189. Uekama K, et al,. Improvement of dissolution and absorption characteristics of phenytoin by a water-soluble β-cyclodextrin- epichlorohydrin polymer. Int J Pharm 1985; 23: 35-42. (Pubitemid 15159580)
190. Tanino T, et al,. Effect of sugar-modified β-cyclodextrins on dissolution and absorption characteristics of phenytoin. Biol Pharm Bull 1999; 22: 298-304. (Pubitemid 29171900)
191. 7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation. Int J Pharm 1998; 165: 69-78. (Pubitemid 28218345)
192. Elkheshen SA, et al,. Inclusion complexes of piroxicam with β-cyclodextrin derivatives in comparison with the natural β-cyclodextrin-2nd communication: in vitro and in vivo drug availability. Pharm Ind 2002; 64: 708-715.
193. Woodcock BG, et al,. Supermolecular inclusion of piroxicam with β-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm 1993; 12: 12-28.
194. Kimura E, et al,. Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymph. Gen Pharmacol 1997; 28: 695-698. (Pubitemid 27244419)
195. Deroubaix X, et al,. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and b-cyclodextrin, in healthy-subjects under single-dose and steady-state conditions. Eur J Clin Pharmacol 1995; 47: 531-536.
196. McEwen J,. Clinical pharmacology of piroxicam-β-cyclodextrin. Implications for innovative patient care. Clin Drug Investig 2000; 19 (Suppl. 2): 27-31. (Pubitemid 30348980)
197. Wempe MF, et al,. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin. Int J Pharm 2008; 346: 25-37. (Pubitemid 350110509)
198. Chavanpatil M, et al,. Enhancement of oral bioavailability of rofecoxib using β-cyclodextrin. J Incl Phenom Macroc Chem 2002; 44: 145-149. (Pubitemid 38075680)
199. Kaukonen AM, et al,. Water-soluble β-cyclodextrins in pediatric oral solutions of spironolactone: preclinical evaluation of spironolactone bioavailability from solutions of β-cyclodextrin derivatives in rats. J Pharm Pharmacol 1998; 50: 611-619. (Pubitemid 28297224)
200. Soliman OAE, et al,. Amorphous spirolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int J Pharm 1997; 149: 73-83. (Pubitemid 27195026)
201. Seo H, et al,. Enhancement of oral bioavailability of spironolactone by β- and γ-cyclodextrin complexations. Chem Pharm Bull 1983; 31: 286-291. (Pubitemid 13122243)
202. Arima H, et al,. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci 2001; 90: 690-701. (Pubitemid 32530445)
203. Veiga F, et al,. Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes. Int J Pharm 2000; 202: 165-171. (Pubitemid 30466243)
204. Kimura K, et al,. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-β- cyclodextrin complex. Chem Pharm Bull 2000; 48: 646-650. (Pubitemid 30321988)
205. Moffat AC, et al., ed. Clarke's Analysis of Drugs and Poisons, 3rd edn. Vol. 2. London: Pharmaceutical Press, 2004.
206. Carrier RL, et al,. The ultility of cyclodextrins for enhancing oral bioavailability. J Controlled Release 2007; 123: 78-99. (Pubitemid 47566400)
207. Dahan A, et al,. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: Mechanistic modeling and application to progesterone. J Pharm Sci 2010; 99: 2739-2749.
208. Loftsson T,. Cyclodextrins and the biopharmaceutics classification system of drugs. J Incl Phenom Macroc Chem 2002; 44: 63-67. (Pubitemid 38075665)
209. Loftsson T, et al,. Role of cyclodextrins in improving oral drug delivery. Am J Drug Deliv 2004; 2: 261-275. (Pubitemid 40045491)
210. Karlsson JP, Artursson P,. A method for the determination of cellular permeability coefficients and aqueous boundary layer thickness in monolayers of intestinal epithelia (Caco-2) cells grown in permeable filter chambers. Int J Pharm 1991; 71: 55-64.
211. Youdim KA, et al,. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 2003; 8: 997-1003. (Pubitemid 37468418)
212. Zuo Z, et al,. Flutamide-hydroxypropyl-β-cyclodextrin complex: formulation, physical characterization, and absorption using the caco-2 in vitro model. J Pharm Pharm Sci 2000; 3: 220-227.
213. Yavuz B, et al,. Alternative oral exemestane formulation: improved dissolution and permeation. Int J Pharm 2010; 398: 137-145.
214. Kuang H,-et al. Transport research of ibuprofen/HP-β-CD system in the Caco-2 monolayer model. Zhongguo Xinyao Zazhi 2008; 34: 1037-1041.
215. Lambert D, et al,. Methyl-β-cyclodextrin increases permeability of caco-2 cell monolayers by displacing specific claudins from cholesterol rich domains associated with tight junctions. Cell Physiol Biochem 2007; 20: 495-506. (Pubitemid 47340610)
216. Ruell JA, et al,. PAMPA-a drug absorption in vitro model 5. Unstirred water layer in iso-pH mapping assay and pKaflux-optimized design (pOH-PAMPA). Eur J Pharm Sci 2003; 20: 393-402. (Pubitemid 37491433)
217. Avdeef A, et al,. PAMPA-a drug absorption in vitro model 11. Matching the in vivo unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci 2004; 22: 365-374. (Pubitemid 38953895)
218. Avdeef A, et al,. PAMPA-critical factors for better predictions of absorption. J Pharm Sci 2007; 96: 2893-2909. (Pubitemid 350221191)
219. Brewster ME, et al,. Effect of the unstirred water layer on permeability enhancement by hydrophilic cyclodextrins. Int J Pharm 2007; 342: 250-253. (Pubitemid 47263497)
220. Giacomini KM, et al,. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236.
221. Bansil R, Turner BS,. Mucin structure, aggregation, physiological functions and biomedical applications. Curr Opin Colloid Interface Sci 2006; 11: 164-170. (Pubitemid 43867390)
222. Lennernäs H,. Human intestinal permeability. J Pharm Sci 1998; 87: 403-410. (Pubitemid 28175799)
223. Norris DA, et al,. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998; 34: 135-154. (Pubitemid 28535109)
224. Khanvilkar K, et al,. Drug transfer through mucus. Adv Drug Deliv Rev 2001; 48: 173-193. (Pubitemid 32434402)
225. Lee SP, Nicholls JF,. Diffusion of charged ions in mucus gel: effect of net charge. Biorheology 1987; 24: 565-569. (Pubitemid 18021580)
226. Olmsted SS, et al,. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001; 81: 1930-1937. (Pubitemid 32917145)
227. Cone RA,. Barrier properties of mucus. Adv Drug Deliv Rev 2009; 61: 75-85.
228. Cone R,. Mucus. In:, Ogra PL, et al, ed. Mucosal Immunology. San Diego, CA: Academic Press, 1999: 43-63.
229. Behrens I, et al,. Transport of lipophilic drug molecules in new mucus-secreting cell culture model based on HT29-MTX cells. Pharm Res 2001; 18: 1138-1145. (Pubitemid 32900399)
230. Smith EW, Maibach HI, eds. Percutaneous Penetration Enhancers. Boca Raton, FL: CRC Press, 1995.
231. Whitehead K, Mitragotri S,. Mechanistic analysis of chemical permeation enhancers for oral drug delivery. Pharm Res 2008; 25: 1412-1419.
232. Rai V, et al,. A transdermal review on permeation of drug formulations, modifier compounds and delivery methods. J Drug Deliv Sci Technol 2010; 20: 75-87.
233. Brouwers J, et al,. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J Pharm Sci 2009; 98: 2549-2572.
234. Yamagata T, et al,. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 2007; 35: 1142-1148. (Pubitemid 46956435)
235. Higuchi T,. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1960; 11: 85-97.
236. Idson B,. Biophysical factors in skin penetration. J Soc Cosmet Chem 1971; 22: 615-634.
237. Másson M, et al,. Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical considerations. Chem Pharm Bull 2005; 53: 958-964. (Pubitemid 41327688)
238. Pohl P, et al,. The size of the unstirred layer as a function of the solute diffusion coefficient. Biophys J 1998; 75: 1403-1409. (Pubitemid 28397609)
239. Zwolinski BJ, et al,. Diffusion and membrane permeability. I. J Phys Colloid Chem 1949; 53: 1426-1453.
240. Flynn GL, et al,. Total mathematical resolution of diffusion layer control of barrier flux. J Pharm Sci 1972; 61: 312-314.
241. Flynn GL, Yalkowsky SH,. Correlation and prediction of mass transport across membranes I: influence of alkyl chain length on flux-determining properties of barrier and diffusant. J Pharm Sci 1972; 61: 838-852.
242. Loftsson T, et al,. 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formations. Eur J Pharm Sci 1994; 1: 175-180. (Pubitemid 24063815)